Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP277504.RA9eZNoatbspXChIgEOA-k-NYgyy-KS9UcIRYpG-P4s8E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP277504.RA9eZNoatbspXChIgEOA-k-NYgyy-KS9UcIRYpG-P4s8E130_assertion type Assertion NP277504.RA9eZNoatbspXChIgEOA-k-NYgyy-KS9UcIRYpG-P4s8E130_head.
- NP277504.RA9eZNoatbspXChIgEOA-k-NYgyy-KS9UcIRYpG-P4s8E130_assertion description "[We have observed that molecular response, as defined by a PCR-negative status during the first year of therapy, along with beta 2-microglobulin (beta 2M), was the most important variable associated with failure-free survival (FFS) in follicular lymphoma (FL).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP277504.RA9eZNoatbspXChIgEOA-k-NYgyy-KS9UcIRYpG-P4s8E130_provenance.
- NP277504.RA9eZNoatbspXChIgEOA-k-NYgyy-KS9UcIRYpG-P4s8E130_assertion evidence source_evidence_literature NP277504.RA9eZNoatbspXChIgEOA-k-NYgyy-KS9UcIRYpG-P4s8E130_provenance.
- NP277504.RA9eZNoatbspXChIgEOA-k-NYgyy-KS9UcIRYpG-P4s8E130_assertion SIO_000772 10707796 NP277504.RA9eZNoatbspXChIgEOA-k-NYgyy-KS9UcIRYpG-P4s8E130_provenance.
- NP277504.RA9eZNoatbspXChIgEOA-k-NYgyy-KS9UcIRYpG-P4s8E130_assertion wasDerivedFrom befree-2016 NP277504.RA9eZNoatbspXChIgEOA-k-NYgyy-KS9UcIRYpG-P4s8E130_provenance.
- NP277504.RA9eZNoatbspXChIgEOA-k-NYgyy-KS9UcIRYpG-P4s8E130_assertion wasGeneratedBy ECO_0000203 NP277504.RA9eZNoatbspXChIgEOA-k-NYgyy-KS9UcIRYpG-P4s8E130_provenance.